March 11 (Reuters) - Gilead Sciences Inc GILD.O:
GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION
GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS
GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS
GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS
GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTS
Source text: [ID:]
Further company coverage: GILD.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.